Despite a consistent decline in incidence and mortality for more than a decade, lung cancer
continues to rank as the leading cause of cancer mortality. 1, 2 In incidence it is second only …

Importance Transgender and gender-diverse individuals face unique challenges, including
barriers to health care access and inequities in treatment, that may influence cancer risk and …

In line with increasing numbers of transgender (trans) and gender nonbinary people
requesting hormone treatment, the body of available research is expanding. More clinical …

Importance Limited prior research suggests that transgender and gender diverse (TGD)
people may have higher mortality rates than cisgender people. Objective To estimate overall …

Abstract Context Approximately 0.4–1.3% of the worldwide population is transgender.
Although the exact prevalence is unknown, there is an increase in open identification as …

Transgender women are assigned male at birth but identified as women. The incidence of
gender dysphoria is estimated to be around 1% of the population. Gender dysphoria may be …

Advances in antiretroviral therapy (ART) have made it possible for persons with human
immunodeficiency virus (HIV) to live a lifespan approaching that of people without HIV …

PURPOSE: Approximately 1.6% of adult Americans identify as transgender (TG) or
nonbinary (NB) and many take gender-affirming hormone therapy (GAHT). Little data exist to …

Abstract Transgender individuals represent 0.55% of the US population, equivalent to 1.4
million transgender adults. In transgender women, feminisation can include a number of …

There is evidence that gender-affirming hormone treatment (GAHT) for transgender
individuals modulates their risk for specific malignancies including breast and prostate …